Insider Selling: LivaNova (NASDAQ:LIVN) Director Sells $187,266.00 in Stock

LivaNova PLC (NASDAQ:LIVN) Director Brooke Story sold 2,300 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $81.42, for a total value of $187,266.00. Following the transaction, the director directly owned 7,488 shares in the company, valued at approximately $609,672.96. This represents a 23.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

LivaNova Stock Down 1.0%

Shares of LIVN opened at $78.18 on Friday. The company has a market cap of $4.31 billion, a PE ratio of 23.13 and a beta of 0.87. The business has a fifty day moving average of $80.46 and a 200 day moving average of $73.29. LivaNova PLC has a 52-week low of $48.82 and a 52-week high of $85.76. The company has a quick ratio of 1.21, a current ratio of 1.45 and a debt-to-equity ratio of 0.22.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings data on Thursday, August 6th. The company reported $1.26 EPS for the quarter, topping the consensus estimate of $1.09 by $0.17. LivaNova had a net margin of 12.82% and a return on equity of 16.35%. The company had revenue of $390.59 million during the quarter, compared to analyst estimates of $380.50 million. During the same period in the previous year, the firm earned $1.05 earnings per share. LivaNova’s quarterly revenue was up 10.8% compared to the same quarter last year. On average, sell-side analysts expect that LivaNova PLC will post 3.77 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Mizuho increased their target price on LivaNova from $90.00 to $95.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 15th. Weiss Ratings raised shares of LivaNova from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, August 18th. Stifel Nicolaus set a $85.00 price target on shares of LivaNova in a report on Wednesday, August 5th. Freedom Capital raised shares of LivaNova to a “hold” rating in a research note on Tuesday, June 30th. Finally, Needham & Company LLC lifted their price objective on shares of LivaNova from $81.00 to $93.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Six analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $84.12.

Hedge Funds Weigh In On LivaNova

Hedge funds and other institutional investors have recently made changes to their positions in the company. Tidal Investments LLC purchased a new position in shares of LivaNova during the second quarter valued at $204,000. WINTON GROUP Ltd purchased a new stake in LivaNova in the second quarter worth about $4,824,000. Integrated Wealth Concepts LLC purchased a new stake in LivaNova in the second quarter worth about $119,000. Squarepoint Ops LLC bought a new position in LivaNova during the 2nd quarter worth about $1,418,000. Finally, Allworth Financial LP grew its holdings in LivaNova by 93.5% during the 2nd quarter. Allworth Financial LP now owns 298 shares of the company’s stock worth $25,000 after acquiring an additional 144 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.